You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PVRIG antibody

Showing 1 - 25 of 5,456
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cancer, Ovarian Cancer, Breast Cancer Trial in United States (COM701, COM701 with Opdivo (Nivolumab).)

Recruiting
  • Advanced Cancer
  • +9 more
  • COM701
  • COM701 with Opdivo (Nivolumab).
  • Los Angeles, California
  • +10 more
Jan 25, 2022

Advanced Tumor Trial (PM1009 injection)

Not yet recruiting
  • Advanced Tumor
  • PM1009 injection
  • (no location specified)
Nov 7, 2022

Advanced Cancer, Ovarian Cancer, Lung Cancer Trial in United States (Dose escalation: COM902 monotherapy., Evaluation of

Recruiting
  • Advanced Cancer
  • +6 more
  • Dose escalation: COM902 monotherapy.
  • +3 more
  • Grand Rapids, Michigan
  • +5 more
Aug 8, 2022

Endometrial Tumors, Ovarian Cancer, Solid Tumor Trial in United States (COM701 in combination with BMS-986207 and nivolumab.)

Recruiting
  • Endometrial Neoplasms
  • +3 more
  • COM701 in combination with BMS-986207 and nivolumab.
  • Chicago, Illinois
  • +8 more
Aug 8, 2022

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Respiratory Syncytial Virus Infections Trial in China (TNM001, )

Not yet recruiting
  • Respiratory Syncytial Virus Infections
  • TNM001
  • placebo
  • Beijing, Beijing, China
  • +38 more
Oct 11, 2023

Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,

Not yet recruiting
  • Her 2 Positive Breast Cancer
  • +2 more
  • Sacituzumab Govitecan
  • +2 more
  • Boston, Massachusetts
  • +1 more
Oct 25, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Rotavirus Infections, Diarrhea Trial (IRV on a 0- and 28-day schedule, IRV on a 0-, 28- and 56-day schedule, Placebo on Day 0,

Not yet recruiting
  • Rotavirus Infections
  • Diarrhea
  • IRV on a 0- and 28-day schedule
  • +3 more
  • (no location specified)
Oct 8, 2023

Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)

Not yet recruiting
  • Stage III Non-small Cell Lung Cancer
  • (no location specified)
Jun 3, 2023

Breast Cancer Trial in China (TQB2102 for injection)

Not yet recruiting
  • Breast Cancer
  • TQB2102 for injection
  • Hefei, Anhui, China
  • +20 more
Nov 1, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer Trial (ADU-1805, Pembrolizumab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
May 3, 2023

NSCLC Trial in Beijing, Tianjin (TQB2450 injection, docetaxel injection matching , AL2846 capsules, TQB2450 matching , docetaxel

Recruiting
  • Non-small Cell Lung Cancer
  • TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules
  • TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo
  • Beijing, Beijing, China
  • +2 more
Jun 19, 2023

Nasopharyngeal Carcinoma, Maintenance Therapy Trial in Guangzhou (Capecitabine/Placebo combined with treprizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Maintenance Therapy
  • Capecitabine/Placebo combined with treprizumab
  • Guangzhou, Guangdong, China
    SunYat-senU
May 11, 2023

HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

Not yet recruiting
  • HER2-positive Colorectal Cancer
  • HER2-positive Biliary Tract Cancer
  • Beijing, State*, China
    Peking University cancer hospital & institution
Aug 2, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Advanced or Metastatic Solid Tumors Trial in Toulouse, Villejuif, Barcelona (W0101 - Cohort A1, W0101 - Cohort A2, W0101 -

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • W0101 - Cohort A1
  • +2 more
  • Toulouse, France
  • +2 more
Dec 19, 2022

Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)

Not yet recruiting
  • Melanoma
  • +16 more
  • Darlinghurst, New South Wales, Australia
  • +3 more
May 12, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Leptomeningeal Disease Trial in Germany (Nivolumab [Opdivo])

Recruiting
  • Leptomeningeal Disease
  • Nivolumab [Opdivo]
  • Freiburg, Germany
  • +6 more
Nov 2, 2022

Solid Tumor Trial (GS-4528, Zimberelimab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Apr 21, 2023